And bacterial contamination becomes a risk once preservatives in the solution begin to degrade, which happens faster at higher temperatures
Mistake 6: Injecting into the wrong tissue layer GLP-1 medications are designed for subcutaneous injection, meaning into the fat layer between the skin and the muscle
For example, combinations of GLP-1/glucagon RA achieve more liver fat content reduction in people with MASLD compared to GLP-1 RA alone despite similar WL, likely due to the direct effect of glucagon on hepatic lipid oxidation [79]
In one trial for semaglutide, participants taking a 2.4 mg once-weekly dose lost 14.9% of their body weight over 68 weeks compared to a weight reduction of 2.4% in the placebo group
Zhao S, Yan Z, Du Y, Li Z, Tang C, Jing L, et al
No, the FDA has not approved any transdermal patch for GLP-1 delivery